Effect of Bevacizumab vs Aflibercept on Visual Acuity
Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion JAMA. 2017 May 9. doi: 10. 1001/jama. 2017. 4568. [Epub ahead of print] IF=37. 684 8조 발표 201576808 201576809 201576823 201576831 201576844 김민서 김지영 배진수 유승주 천경재
Retinal vein occlusion : 40대 이상, 당뇨병성 망막병증 환자에서 가장 흔한 망막 혈관성 질환 INTERVENTIONS Eyes were randomized to receive intravitreal injection of bevacizumab (1. 25 mg; n=182) or aflibercept (2. 0 mg; n=180) every 4 weeks through 6 months. PURPOSE Investigated whether bevacizumab was noninferior to aflibercept for treatment of macular edema due to central retinal or hemiretinal veinocclusion. *Bevacizumab (약 $60/dose) : inhibit VEGF-A *Aflibercept ($1850/dose) : inhibit VEGF-A, VEGF-B, and placental growth factor
Figure 1. Flow chart
* VALS (visual acuity letter score) : 0 -100, higher scores indicate better VA
Limitations 1) lack of a ranibizumab treatment group 2) lack of as-needed treatment groups that were evaluated from baseline 3) relatively short follow-up Conclusions Among patients with macular edema secondary to central retinal or hemiretinal vein occlusion, intravitreal bevacizumab was noninferior to aflibercept with respect to VA after 6 months of treatment.